As of Sep 01
| -0.24 / -4.07%|
The 6 analysts offering 12-month price forecasts for Array Biopharma Inc have a median target of 10.00, with a high estimate of 14.50 and a low estimate of 9.00. The median estimate represents a +76.68% increase from the last price of 5.66.
The current consensus among 7 polled investment analysts is to Buy stock in Array Biopharma Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.